Advertisement

Meta-analysis Comparing Direct Oral Anticoagulants Versus Vitamin K Antagonists After Transcatheter Aortic Valve Implantation

Published:January 08, 2020DOI:https://doi.org/10.1016/j.amjcard.2019.12.039
      Atrial fibrillation (AF) is a common co-morbidity in patients undergoing transcatheter aortic valve implantation (TAVI), but whether direct oral anticoagulants (DOACs) confer similar safety and efficacy compared with vitamin K antagonist (VKA) remains unclear in this population. The aim of our study was to investigate the safety and efficacy of DOACs compared with VKA in patients undergoing TAVI with concomitant indication of oral anticoagulation. PUBMED and EMBASE were searched through October 2019 for studies comparing DOACs versus VKA in patients undergoing TAVI with indication of oral anticoagulation. The main efficacy outcomes were all-cause mortality and stroke whereas the main safety outcome was major and/or life-threatening bleeding. Our search identified 5 eligible studies including 2,569 patients. Majority of patients had atrial fibrillation as indication of anticoagulation. There were no significant differences in all-cause mortality, major and/or life-threatening bleeding, and stroke in patients treated with DOACs versus VKA (odds ratio [OR] 1.07, 95% confidence interval [CI] [0.73 to 1.57], p = 0.72, OR = 0.85, 95% CI [0.64 to 1.12], p = 0.24, OR 1.52, 95% CI [0.93 to 2.48], p = 0.09, respectively). In conclusion, in patients undergoing TAVI with concomitant indication for oral anticoagulation, all-cause mortality, major and/or life-threatening bleeding, and stroke were similar between DOACs and VKA. Further large scale randomized controlled trials are needed to search the optimal oral anticoagulation regimen in this population.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Leon MB
        • Smith CR
        • Mack M
        • Miller DC
        • Moses JW
        • Svensson LG
        • Tuzcu EM
        • Webb JG
        • Fontana GP
        • Makkar RR
        • Brown DL
        • Block PC
        • Guyton RA
        • Pichard AD
        • Bavaria JE
        • Herrmann HC
        • Douglas PS
        • Petersen JL
        • Akin JJ
        • Anderson WN
        • Wang D
        • Pocock S
        Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery.
        N Engl J Med. 2010; 363: 1597-1607
        • Leon MB
        • Smith CR
        • Mack MJ
        • Makkar RR
        • Svensson LG
        • Kodali SK
        • Thourani VH
        • Tuzcu EM
        • Miller DC
        • Herrmann HC
        • Doshi D
        • Cohen DJ
        • Pichard AD
        • Kapadia S
        • Dewey T
        • Babaliaros V
        • Szeto WY
        • Williams MR
        • Kereiakes D
        • Zajarias A
        • Greason KL
        • Whisenant BK
        • Hodson RW
        • Moses JW
        • Trento A
        • Brown DL
        • Fearon WF
        • Pibarot P
        • Hahn RT
        • Jaber WA
        • Anderson WN
        • Alu MC
        • Webb JG
        Transcatheter or Surgical aortic-valve replacement in intermediate-risk patients.
        N Engl J Med. 2016; 374: 1609-1620
        • Mack MJ
        • Leon MB
        • Thourani VH
        • Makkar R
        • Kodali SK
        • Russo M
        • Kapadia SR
        • Malaisrie SC
        • Cohen DJ
        • Pibarot P
        • Leipsic J
        • Hahn RT
        • Blanke P
        • Williams MR
        • McCabe JM
        • Brown DL
        • Babaliaros V
        • Goldman S
        • Szeto WY
        • Genereux P
        • Pershad A
        • Pocock SJ
        • Alu MC
        • Webb JG
        • Smith CR
        Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients.
        N Engl J Med. 2019; 380: 1695-1705
        • Popma JJ
        • Deeb GM
        • Yakubov SJ
        • Mumtaz M
        • Gada H
        • O'Hair D
        • Bajwa T
        • Heiser JC
        • Merhi W
        • Kleiman NS
        • Askew J
        • Sorajja P
        • Rovin J
        • Chetcuti SJ
        • Adams DH
        • Teirstein PS
        • Zorn 3rd, GL
        • Forrest JK
        • Tchetche D
        • Resar J
        • Walton A
        • Piazza N
        • Ramlawi B
        • Robinson N
        • Petrossian G
        • Gleason TG
        • Oh JK
        • Boulware MJ
        • Qiao H
        • Mugglin AS
        • Reardon MJ
        Transcatheter ortic-valve replacement with a self-expanding valve in low-risk patients.
        N Engl J Med. 2019; 380: 1706-1715
        • Smith CR
        • Leon MB
        • Mack MJ
        • Miller DC
        • Moses JW
        • Svensson LG
        • Tuzcu EM
        • Webb JG
        • Fontana GP
        • Makkar RR
        • Williams M
        • Dewey T
        • Kapadia S
        • Babaliaros V
        • Thourani VH
        • Corso P
        • Pichard AD
        • Bavaria JE
        • Herrmann HC
        • Akin JJ
        • Anderson WN
        • Wang D
        • Pocock SJ
        Transcatheter versus surgical aortic-valve replacement in high-risk patients.
        N Engl J Med. 2011; 364: 2187-2198
        • Tarantini G
        • Mojoli M
        • Windecker S
        • Wendler O
        • Lefevre T
        • Saia F
        • Walther T
        • Rubino P
        • Bartorelli AL
        • Napodano M
        • D'Onofrio A
        • Gerosa G
        • Iliceto S
        • Vahanian A
        Prevalence and impact of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the SOURCE XT prospective multicenter registry.
        JACC Cardiovasc Interv. 2016; 9: 937-946
        • Adams DH
        • Popma JJ
        • Reardon MJ
        • Yakubov SJ
        • Coselli JS
        • Deeb GM
        • Gleason TG
        • Buchbinder M
        • Hermiller Jr., J
        • Kleiman NS
        • Chetcuti S
        • Heiser J
        • Merhi W
        • Zorn G
        • Tadros P
        • Robinson N
        • Petrossian G
        • Hughes GC
        • Harrison JK
        • Conte J
        • Maini B
        • Mumtaz M
        • Chenoweth S
        • Oh JK
        Transcatheter aortic-valve replacement with a self-expanding prosthesis.
        N Engl J Med. 2014; 370: 1790-1798
        • Vora AN
        • Dai D
        • Matsuoka R
        • Harrison JK
        • Hughes GCt
        • Sherwood MW
        • Piccini JP
        • Bhardwaj B
        • Lopes RD
        • Cohen D
        • Holmes Jr., DR
        • Thourani VH
        • Peterson E
        • Kirtane A
        • Kapadia S
        • Vemulapalli S
        Incidence, management, and associated clinical outcomes of new-onset atrial fibrillation following transcatheter aortic valve replacement: an analysis from the STS/ACC TVT registry.
        JACC Cardiovasc Interv. 2018; 11: 1746-1756
        • Genereux P
        • Cohen DJ
        • Mack M
        • Rodes-Cabau J
        • Yadav M
        • Xu K
        • Parvataneni R
        • Hahn R
        • Kodali SK
        • Webb JG
        • Leon MB
        Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement.
        J Am Coll Cardiol. 2014; 64: 2605-2615
        • Granger CB
        • Alexander JH
        • McMurray JJ
        • Lopes RD
        • Hylek EM
        • Hanna M
        • Al-Khalidi HR
        • Ansell J
        • Atar D
        • Avezum A
        • Bahit MC
        • Diaz R
        • Easton JD
        • Ezekowitz JA
        • Flaker G
        • Garcia D
        • Geraldes M
        • Gersh BJ
        • Golitsyn S
        • Goto S
        • Hermosillo AG
        • Hohnloser SH
        • Horowitz J
        • Mohan P
        • Jansky P
        • Lewis BS
        • Lopez-Sendon JL
        • Pais P
        • Parkhomenko A
        • Verheugt FW
        • Zhu J
        • Wallentin L
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Patel MR
        • Mahaffey KW
        • Garg J
        • Pan G
        • Singer DE
        • Hacke W
        • Breithardt G
        • Halperin JL
        • Hankey GJ
        • Piccini JP
        • Becker RC
        • Nessel CC
        • Paolini JF
        • Berkowitz SD
        • Fox KA
        • Califf RM
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Windecker S
        • Tijssen J
        • Giustino G
        • Guimaraes AH
        • Mehran R
        • Valgimigli M
        • Vranckx P
        • Welsh RC
        • Baber U
        • van Es GA
        • Wildgoose P
        • Volkl AA
        • Zazula A
        • Thomitzek K
        • Hemmrich M
        • Dangas GD
        Trial design: rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: rationale and design of the GALILEO study.
        Am Heart J. 2017; 184: 81-87
      1. Todd Neale. GALILEO trial of rivaroxaban after TAVR stopped early for harm, 2018.

        • Liberati A
        • Altman DG
        • Tetzlaff J
        • Mulrow C
        • Gotzsche PC
        • Ioannidis JP
        • Clarke M
        • Devereaux PJ
        • Kleijnen J
        • Moher D
        The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
        J Clin Epidemiol. 2009; 62: e1-34
        • Stang A
        Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.
        Eur J Epidemiol. 2010; 25: 603-605
        • Higgins JP
        • Thompson SG
        • Deeks JJ
        • Altman DG
        Measuring inconsistency in meta-analyses.
        Bmj. 2003; 327: 557-560
        • Geis NA
        • Kiriakou C
        • Chorianopoulos E
        • Uhlmann L
        • Katus HA
        • Bekeredjian R
        NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation.
        Clin Res Cardiol. 2018; 107: 799-806
        • Jochheim D
        • Barbanti M
        • Capretti G
        • Stefanini GG
        • Hapfelmeier A
        • Zadrozny M
        • Baquet M
        • Fischer J
        • Theiss H
        • Todaro D
        • Chieffo A
        • Presbitero P
        • Colombo A
        • Massberg S
        • Tamburino C
        • Mehilli J
        Oral anticoagulant type and outcomes after transcatheter aortic valve replacement.
        JACC Cardiovasc Interv. 2019; 12: 1566-1576
        • Kosmidou I
        • Liu Y
        • Alu MC
        • Liu M
        • Madhavan M
        • Chakravarty T
        • Makkar R
        • Thourani VH
        • Biviano A
        • Kodali S
        • Leon MB
        Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve replacement in patients with atrial fibrillation.
        JACC Cardiovasc Interv. 2019; 12: 1580-1589
        • Seeger J
        • Gonska B
        • Rodewald C
        • Rottbauer W
        • Wohrle J
        Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement.
        JACC Cardiovasc Interv. 2017; 10: 66-74
        • Kalogeras K
        • Jabbour RJ
        • Ruparelia N
        • Watson S
        • Kabir T
        • Naganuma T
        • Vavuranakis M
        • Nakamura S
        • Malik IS
        • Mikhail G
        • Dalby M
        • Panoulas V
        Comparison of warfarin versus DOACs in patients with concomitant indication for oral anticoagulation undergoing TAVI; results from the ATLAS registry.
        J Thromb Thrombolysis. 2019;
        • Kappetein AP
        • Head SJ
        • Genereux P
        • Piazza N
        • van Mieghem NM
        • Blackstone EH
        • Brott TG
        • Cohen DJ
        • Cutlip DE
        • van Es GA
        • Hahn RT
        • Kirtane AJ
        • Krucoff MW
        • Kodali S
        • Mack MJ
        • Mehran R
        • Rodes-Cabau J
        • Vranckx P
        • Webb JG
        • Windecker S
        • Serruys PW
        • Leon MB
        Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document.
        J Am Coll Cardiol. 2012; 60: 1438-1454
        • Nishimura RA
        • Otto CM
        • Bonow RO
        • Carabello BA
        • Erwin 3rd, JP
        • Fleisher LA
        • Jneid H
        • Mack MJ
        • McLeod CJ
        • O'Gara PT
        • Rigolin VH
        • Sundt 3rd, TM
        • Thompson A
        2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.
        Circulation. 2017; 135: e1159-e1195
        • Baumgartner H
        • Falk V
        • Bax JJ
        • De Bonis M
        • Hamm C
        • Holm PJ
        • Iung B
        • Lancellotti P
        • Lansac E
        • Munoz DR
        • Rosenhek R
        • Sjogren J
        • Mas PT
        • Vahanian A
        • Walther T
        • Wendler O
        • Windecker S
        • Zamorano JL
        2017 ESC/EACTS guidelines for the management of valvular heart disease.
        Rev Esp Cardiol (Engl Ed). 2018; 71: 110
        • Giugliano RP
        • Ruff CT
        • Braunwald E
        • Murphy SA
        • Wiviott SD
        • Halperin JL
        • Waldo AL
        • Ezekowitz MD
        • Weitz JI
        • Spinar J
        • Ruzyllo W
        • Ruda M
        • Koretsune Y
        • Betcher J
        • Shi M
        • Grip LT
        • Patel SP
        • Patel I
        • Hanyok JJ
        • Mercuri M
        • Antman EM
        Edoxaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2013; 369: 2093-2104
        • Connolly SJ
        • Ezekowitz MD
        • Yusuf S
        • Eikelboom J
        • Oldgren J
        • Parekh A
        • Pogue J
        • Reilly PA
        • Themeles E
        • Varrone J
        • Wang S
        • Alings M
        • Xavier D
        • Zhu J
        • Diaz R
        • Lewis BS
        • Darius H
        • Diener HC
        • Joyner CD
        • Wallentin L
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Sardar P
        • Chatterjee S
        • Chaudhari S
        • Lip GY
        New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials.
        J Am Geriatr Soc. 2014; 62: 857-864
        • Carnicelli AP
        • De Caterina R
        • Halperin JL
        • Renda G
        • Ruff CT
        • Trevisan M
        • Nordio F
        • Mercuri MF
        • Antman E
        • Giugliano RP
        Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves.
        Circulation. 2017; 135: 1273-1275
        • Guimaraes PO
        • Pokorney SD
        • Lopes RD
        • Wojdyla DM
        • Gersh BJ
        • Giczewska A
        • Carnicelli A
        • Lewis BS
        • Hanna M
        • Wallentin L
        • Vinereanu D
        • Alexander JH
        • Granger CB
        Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial.
        Clin Cardiol. 2019; 42: 568-571